- Conditions
- Herpes Zoster (HZ), Infectious Diseases, Shingles
- Interventions
- JCXH-105, Shingrix
- Biological
- Lead sponsor
- Immorna Biotherapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 467 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Long Beach, California • Chicago, Illinois + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 4,113
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ceritinib, Pemetrexed, Docetaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 13
- States / cities
- Fayetteville, Arkansas • Hollywood, Florida • Jacksonville, Florida + 10 more
- Conditions
- Aging
- Interventions
- Experimental: Locomotor Learning
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 65 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Fear Conditioning, Avoidance conditioning, Pavlovian fear extinction learning, Willingness to pay to avoid shock
- Behavioral · Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- ACP-196, ACP-196 in combination with pembrolizumab
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Asthma
- Interventions
- ENV-294, Placebo
- Drug
- Lead sponsor
- Enveda Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Jose, California + 17 more
- Conditions
- Influenza
- Interventions
- GSK A/turkey H5N1 Influenza vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 469 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 7
- States / cities
- Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel, 5-hydroxytryptamine subtype 3 receptor antagonist, Neurokinin-1 receptor antagonist, Corticosteroid
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 4
- States / cities
- Lexington, Kentucky • Baltimore, Maryland • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Opioid Use Disorder, Substance Use Disorder
- Interventions
- Treatment as Usual (TAU) (Arm 1), Peer Recovery Support Services (PRSS) + TAU (experimental- Arm 2)
- Behavioral
- Lead sponsor
- Potomac Health Foundations
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Rockville, Maryland
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
- Interventions
- CGT4859
- Drug
- Lead sponsor
- Cogent Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more
- Conditions
- Denture Retention
- Interventions
- Investigational denture adhesive cream, Super Poligrip Free
- Device
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Cancer of Rectum
- Interventions
- combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 5
- States / cities
- Lakewood, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 2 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Rolapitant - Oral, Rolapitant - IV
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- All Conditions
- Interventions
- PCF model
- Other
- Lead sponsor
- Mathematica Policy Research, Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 25,000,000 participants
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- Cladribine, Cytarabine, Decitabine, azacitidine or decitabine, Venetoclax
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Cataract
- Interventions
- Investigational Intraocular Lens Device #1: TECNIS Model ZHR00, Investigational Intraocular Lens Device #2: TECNIS Model ZQR00, TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00
- Device
- Lead sponsor
- Abbott Medical Optics
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 12
- States / cities
- Bakersfield, California • Beverly Hills, California • Sioux City, Iowa + 9 more
- Conditions
- Active Control (Robot on Screen), Adaptive Assistive Robot
- Interventions
- Exercise with Assistive Robot
- Behavioral
- Lead sponsor
- Oregon State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Lebanon, Oregon
- Conditions
- Speech, Memory, Delayed, Sensorineural Hearing Loss
- Interventions
- Sentence stimulus, Speaking style
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 60 Years to 90 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Tobacco Cessation, HIV, AIDS
- Interventions
- Treatment as usual, AIR (Aspirations, Inspiration, Respiration)
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatitis
- Interventions
- Early cholecystectomy with IOC, Late cholecystectomy with IOC
- Procedure
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- EZN-2208, Cetuximab and Irinotecan
- Drug
- Lead sponsor
- Enzon Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Alhambra, California • Bakersfield, California + 30 more
- Conditions
- Advanced Solid Cancers
- Interventions
- BMS-986301, Nivolumab, Ipilimumab
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Neurotoxicity, Neurotoxicity Syndromes, Cytokine Release Syndrome
- Interventions
- Anakinra, Axicabtagene Ciloleucel
- Drug
- Lead sponsor
- Marcela V. Maus, M.D.,Ph.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- COVID, Corona Virus Infection, COVID19
- Interventions
- Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo
- Biological · Other
- Lead sponsor
- Joanne Kurtzberg, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more